These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33606407)

  • 1. Rho kinase (ROCK) inhibitors in the management of corneal endothelial disease.
    Syed ZA; Rapuano CJ
    Curr Opin Ophthalmol; 2021 May; 32(3):268-274. PubMed ID: 33606407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy.
    Kinoshita S; Colby KA; Kruse FE
    Cornea; 2021 Oct; 40(10):1225-1228. PubMed ID: 34481406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, Double-Masked, Pilot Study of Netarsudil 0.02% Ophthalmic Solution for Treatment of Corneal Edema in Fuchs Dystrophy.
    Price MO; Price FW
    Am J Ophthalmol; 2021 Jul; 227():100-105. PubMed ID: 33737034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Functional Restoration of Corneal Endothelial Cells in Fuchs Endothelial Corneal Dystrophy by ROCK Inhibitor (Ripasudil).
    Schlötzer-Schrehardt U; Zenkel M; Strunz M; Gießl A; Schondorf H; da Silva H; Schmidt GA; Greiner MA; Okumura N; Koizumi N; Kinoshita S; Tourtas T; Kruse FE
    Am J Ophthalmol; 2021 Apr; 224():185-199. PubMed ID: 33316261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Topical Rho Kinase Inhibitors in the Treatment of Fuchs Dystrophy After Descemet Stripping Only.
    Macsai MS; Shiloach M
    Cornea; 2019 May; 38(5):529-534. PubMed ID: 30720541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Descemetorhexis Without Grafting for Fuchs Endothelial Dystrophy-Supplementation With Topical Ripasudil.
    Moloney G; Petsoglou C; Ball M; Kerdraon Y; Höllhumer R; Spiteri N; Beheregaray S; Hampson J; DʼSouza M; Devasahayam RN
    Cornea; 2017 Jun; 36(6):642-648. PubMed ID: 28476048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Rho Kinase Inhibitors in Corneal Diseases.
    Futterknecht S; Chatzimichail E; Gugleta K; Panos GD; Gatzioufas Z
    Drug Des Devel Ther; 2024; 18():97-108. PubMed ID: 38264539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Transiently Alters the Morphology of Corneal Endothelial Cells.
    Okumura N; Okazaki Y; Inoue R; Nakano S; Fullwood NJ; Kinoshita S; Koizumi N
    Invest Ophthalmol Vis Sci; 2015 Nov; 56(12):7560-7. PubMed ID: 26618648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Migration of Fuchs Corneal Endothelial Cells by Rho Kinase Inhibition: A Novel Ex Vivo Descemet's Stripping Only Model.
    Parekh M; Miall A; Chou A; Buhl L; Deshpande N; Price MO; Price FW; Jurkunas UV
    Cells; 2024 Jul; 13(14):. PubMed ID: 39056800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot Study of Corneal Clearance With the Use of a Rho-Kinase Inhibitor After Descemetorhexis Without Endothelial Keratoplasty for Fuchs Endothelial Corneal Dystrophy.
    Davies E; Jurkunas U; Pineda R
    Cornea; 2021 Jul; 40(7):899-902. PubMed ID: 33758139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapeutic modality for corneal endothelial disease using Rho-associated kinase inhibitor eye drops.
    Koizumi N; Okumura N; Ueno M; Kinoshita S
    Cornea; 2014 Nov; 33 Suppl 11():S25-31. PubMed ID: 25289721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rho-associated kinase inhibitor eye drop treatment as a possible medical treatment for Fuchs corneal dystrophy.
    Koizumi N; Okumura N; Ueno M; Nakagawa H; Hamuro J; Kinoshita S
    Cornea; 2013 Aug; 32(8):1167-70. PubMed ID: 23715376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on ripasudil for the treatment of glaucoma and ocular hypertension.
    Testa V; Ferro Desideri L; Della Giustina P; Traverso CE; Iester M
    Drugs Today (Barc); 2020 Sep; 56(9):599-608. PubMed ID: 33025953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Series: Novel Utilization of Rho-Kinase Inhibitor for the Treatment of Corneal Edema.
    Davies E
    Cornea; 2021 Jan; 40(1):116-120. PubMed ID: 33269892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.
    Tanna AP; Johnson M
    Ophthalmology; 2018 Nov; 125(11):1741-1756. PubMed ID: 30007591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rho-kinase inhibitors: Role in corneal endothelial disorders.
    Singh NK; Sahu SK
    Semin Ophthalmol; 2023 Jan; 38(1):9-14. PubMed ID: 35993293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Descemet's stripping without endothelial keratoplasty.
    Garcerant D; Hirnschall N; Toalster N; Zhu M; Wen L; Moloney G
    Curr Opin Ophthalmol; 2019 Jul; 30(4):275-285. PubMed ID: 31033737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative Use of Rho-Kinase Inhibitors has Beneficial Effect on Corneal Endothelium after Phacoemulsification.
    Alkharashi M; AlAbbasi O; Magliyah M
    Middle East Afr J Ophthalmol; 2019; 26(4):246-249. PubMed ID: 32153339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Rho Kinase Inhibitors in Corneal Endothelial Dysfunction.
    Okumura N; Kinoshita S; Koizumi N
    Curr Pharm Des; 2017; 23(4):660-666. PubMed ID: 27917718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcorneal freezing and topical Rho-kinase inhibitor treatment in Fuchs endothelial corneal dystrophy.
    Menzel-Severing J; Schrader S; Schlötzer-Schrehardt U; Geerling G
    Eye (Lond); 2022 Apr; 36(4):891-893. PubMed ID: 33846576
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.